Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Quark gets access to Alnylam's InterfeRx program

Executive Summary

Quark Biotech (creating treatments for fibrotic and ischemic conditions in the eyes, kidney, and lungs) has received rights to use Alnylam Pharmaceuticals's (developing RNAi drug candidates for respiratory, neurological, cardiovascular, and musculoskeletal conditions and infectious diseases) RNAi patents--through the InterfeRx licensing program--to discover, develop, and market RNAi therapeutics that target p53 and RTP801 genes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies